Short Interest in OPKO Health, Inc. (NASDAQ:OPK) Decreases By 14.0%

OPKO Health, Inc. (NASDAQ:OPK) was the target of a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 84,800,000 shares, a drop of 14.0% from the November 30th total of 98,570,000 shares. Currently, 27.4% of the company’s shares are sold short. Based on an average daily volume of 3,950,000 shares, the short-interest ratio is currently 21.5 days.

Insider Transactions at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 125,000 shares of the stock in a transaction on Friday, December 13th. The stock was purchased at an average price of $1.59 per share, with a total value of $198,750.00. Following the completion of the purchase, the chief executive officer now owns 212,536,477 shares of the company’s stock, valued at approximately $337,932,998.43. This trade represents a 0.06 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased 1,304,255 shares of company stock worth $2,024,605 in the last three months. Insiders own 47.26% of the company’s stock.

Institutional Investors Weigh In On OPKO Health

Large investors have recently made changes to their positions in the stock. Rubric Capital Management LP lifted its position in OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after acquiring an additional 4,284,336 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in OPKO Health by 142.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,490,992 shares of the biotechnology company’s stock worth $2,227,000 after purchasing an additional 876,272 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of OPKO Health in the second quarter valued at approximately $592,000. Y.D. More Investments Ltd bought a new position in shares of OPKO Health during the second quarter valued at $1,840,000. Finally, BNP Paribas Financial Markets increased its stake in shares of OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 217,450 shares during the period. Institutional investors and hedge funds own 64.63% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Thursday, September 26th. StockNews.com downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Thursday. Barrington Research reiterated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th. Finally, Piper Sandler restated an “overweight” rating and issued a $3.00 price target on shares of OPKO Health in a report on Tuesday, September 17th.

OPKO Health Stock Performance

Shares of NASDAQ OPK opened at $1.48 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock has a 50 day moving average price of $1.55 and a 200 day moving average price of $1.48. The stock has a market capitalization of $1.01 billion, a PE ratio of -7.79 and a beta of 1.62. OPKO Health has a 52 week low of $0.85 and a 52 week high of $1.76.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.